CONTEXT: The typically indolent behavior of pituitary tumors is juxtaposed with high rates of tumor cell invasion into adjacent dural structures, and occasional aggressive behavior. Although clinically significant invasion and malignant transformation remain uncommon, there are limited treatment options available for the management of these aggressive tumors. Recently, case reports have described efficacy of temozolomide for the treatment of aggressive pituitary tumors. DESIGN: Seven patients with aggressive pituitary tumors have been treated with temozolomide. We compared O(6)-methylguanine methyltransferase (MGMT) promoter methylation and MGMT expression in 14 surgical specimens from these seven patients and correlated these molecular features with the clinical response to temozolomide. RESULTS: Significant tumor regression was seen in two patients (29%), a 20% reduction in tumor volume with subsequent stable tumor size was noted in one patient, arrest of tumor growth occurred in three patients, and progressive metastatic disease developed during treatment in one patient. The DNA promoter site for MGMT was unmethylated in all 14 adequate specimens, and variable MGMT expression was seen in all 14 cases. There was no correlation between MGMT expression and clinical outcomes. CONCLUSIONS: We conclude that medical therapy with temozolomide can be helpful in the management of life-threatening pituitary tumors that have failed to respond to conventional treatments. The optimal duration of treatment in patients with stabilization or reduction of tumor size has not been established, and long-term follow up studies are needed.
CONTEXT: The typically indolent behavior of pituitary tumors is juxtaposed with high rates of tumor cell invasion into adjacent dural structures, and occasional aggressive behavior. Although clinically significant invasion and malignant transformation remain uncommon, there are limited treatment options available for the management of these aggressive tumors. Recently, case reports have described efficacy of temozolomide for the treatment of aggressive pituitary tumors. DESIGN: Seven patients with aggressive pituitary tumors have been treated with temozolomide. We compared O(6)-methylguanine methyltransferase (MGMT) promoter methylation and MGMT expression in 14 surgical specimens from these seven patients and correlated these molecular features with the clinical response to temozolomide. RESULTS: Significant tumor regression was seen in two patients (29%), a 20% reduction in tumor volume with subsequent stable tumor size was noted in one patient, arrest of tumor growth occurred in three patients, and progressive metastatic disease developed during treatment in one patient. The DNA promoter site for MGMT was unmethylated in all 14 adequate specimens, and variable MGMT expression was seen in all 14 cases. There was no correlation between MGMT expression and clinical outcomes. CONCLUSIONS: We conclude that medical therapy with temozolomide can be helpful in the management of life-threatening pituitary tumors that have failed to respond to conventional treatments. The optimal duration of treatment in patients with stabilization or reduction of tumor size has not been established, and long-term follow up studies are needed.
Authors: Dalia L Batista; Xun Zhang; Roger Gejman; Peter J Ansell; Yunli Zhou; Sarah A Johnson; Brooke Swearingen; E Tessa Hedley-Whyte; Constantine A Stratakis; Anne Klibanski Journal: J Clin Endocrinol Metab Date: 2006-08-29 Impact factor: 5.958
Authors: Sahana Kaup; Valerie Grandjean; Rajarshi Mukherjee; Aparna Kapoor; Edward Keyes; Colin B Seymour; Carmel E Mothersill; Paul N Schofield Journal: Mutat Res Date: 2006-01-18 Impact factor: 2.433
Authors: Camilo E Fadul; Andrew L Kominsky; Louise P Meyer; Linda S Kingman; William B Kinlaw; C Harker Rhodes; Clifford J Eskey; Nathan E Simmons Journal: J Neurosurg Date: 2006-10 Impact factor: 5.115
Authors: Shlomo Melmed; Richard Sternberg; David Cook; Anne Klibanski; Philippe Chanson; Vivien Bonert; Mary Lee Vance; David Rhew; David Kleinberg; Ariel Barkan Journal: J Clin Endocrinol Metab Date: 2005-04-12 Impact factor: 5.958
Authors: P J Pernicone; B W Scheithauer; T J Sebo; K T Kovacs; E Horvath; W F Young; R V Lloyd; D H Davis; B L Guthrie; W C Schoene Journal: Cancer Date: 1997-02-15 Impact factor: 6.860
Authors: A J Mixson; T C Friedman; D A Katz; I M Feuerstein; J K Taubenberger; J M Colandrea; J L Doppman; E H Oldfield; B D Weintraub Journal: J Clin Endocrinol Metab Date: 1993-02 Impact factor: 5.958
Authors: A K Annamalai; A F Dean; N Kandasamy; K Kovacs; H Burton; D J Halsall; A S Shaw; N M Antoun; H K Cheow; R W Kirollos; J D Pickard; H L Simpson; S J Jefferies; N G Burnet; M Gurnell Journal: Pituitary Date: 2012-09 Impact factor: 4.107
Authors: Troy H Dillard; S Humayun Gultekin; Johnny B Delashaw; Chris G Yedinak; Edward A Neuwelt; Maria Fleseriu Journal: Pituitary Date: 2011-03 Impact factor: 4.107